Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8994618 | 1.00 | KDM4E (0.59) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL8668029 | 0.98 | KDM4E (0.57) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL1249257 | 0.87 | SMN1; SMN2 (0.53) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL8668036 | 0.85 | NPC1 (0.54) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL12641829 | 0.85 | NPC1 (0.54) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL2964316 | 0.85 | NPC1 (0.54) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL1249910 | 0.84 | HSD17B1 (0.60) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL5346655 | 0.83 | NPC1 (0.53) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL978583 | 0.83 | KDM4E (0.72) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL4948373 | 0.83 | KDM4E (0.64) | KDM4ENPC1RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117416983-A | Naphthoxyhc acid and/or its derivative acid radical intercalation hydrotalcite-like compound and its preparation method | 中国科学院青海盐湖研究所 | 2024-01-19 | — | — | CN | claimed |
| CN-116836081-A | Ether epoxy toughening agent and preparation method and application thereof | 中国林业科学研究院林产化学工业研究所 | 2023-10-03 | — | — | CN | claimed |
| CN-108949002-B | Preparation method of flame-retardant and light-resistant waterborne polyurethane coating for preparing furniture or metal appliances | 浙江家家智能家居有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-10191398-B2 | Electrophotographic photoconductor, image forming apparatus, and process cartridge | RICOH COMPANY, LTD. (JP) | 2019-01-29 | — | — | US | claimed |
| EP-1549598-A4 | NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | CORTICAL PTY LTD (AU) | 2008-01-23 | — | — | EP | claimed |
| US-20060106102-A1 | Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) | Morand, Eric | 2006-05-18 | — | — | US | claimed |
| EP-1549598-A1 | NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | Cortical Pty Ltd (AU) | 2005-07-06 | — | — | EP | claimed |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | ALLEN DARIN ARTHUR (US) | 2003-12-18 | — | — | US | claimed |
| WO-2003104178-A1 | NAPTHTHALENE DERIVATIVES WHICH INHIBIT THE CYTOKINE OR BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | claimed |
| EP-1242366-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| EP-0836592-A1 | AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002249-A1 | NOVEL AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-23 | — | — | WO | claimed |
| EP-4668315-A1 | COMPOSITION FOR FORMING PROTECTIVE FILM FOR SEMICONDUCTOR CHIP MANUFACTURE, SEMICONDUCTOR SUBSTRATE, SEMICONDUCTOR CHIP, AND METHOD FOR MANUFACTURING SEMICONDUCTOR CHIP | Nissan Chemical Corporation (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-20250361419-A1 | COMPOSITION FOR FORMING COATING FILM FOR REMOVING FOREIGN MATTERS AND SEMICONDUCTOR SUBSTRATE | NISSAN CHEMICAL CORPORATION (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4629280-A1 | COMPOSITION FOR FORMING COATING FILM FOR FOREIGN SUBSTANCE REMOVAL, AND SEMICONDUCTOR SUBSTRATE | Nissan Chemical Corporation (JP) | 2025-10-08 | — | — | EP | disclosed |
| EP-0577245-A1 | Photogenerating azo pigments | XEROX CORPORATION (US) | 1994-01-05 | — | — | EP | disclosed |
| US-4115055-A | Mixture of water-insoluble monoazo dyestuffs for coloring textile materials consisting at least partly of linear, aromatic polyesters | ROHNER AG PRATTELN (CH) | 1978-09-19 | — | — | US | disclosed |
| US-3971741-A | DISPERSION PIGMENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | TFPI, HABP2, PLAT | KDM4E 1916/4885NPC1 4290/4885RAB9A 3500/4885 |
| US-20060106102-A1 | Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) | MIF, ARG1, MSR1 | KDM4E 3166/4885NPC1 1590/4885RAB9A 3341/4885 |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | TFPI, SERPINE1, HABP2 | KDM4E 1747/4885NPC1 4012/4885RAB9A 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.